Drugs / KT-333
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05225584 | May 2022 → Mar 2025 | T-cell large granular lymphocyte leukemia, T-cell prolymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05225584 ↗ |
| Route | Intravenous | “administered intravenously” NCT05225584 ↗ |